VRTX

Vertex Pharmaceuticals
D

VRTX

Arincen81/100B

Vertex Pharmaceuticals return on equity (ROE)

Vertex Pharmaceuticals's return on equity is 19.02%: net income of 3.98B USD over the last twelve months on shareholders' equity of 20.91B USD.

Today
19.02%
Average, 5 years
17.01%
Low, 5 years
-5.99%
High, 5 years
26.77%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 3.98B ÷ 20.91B = 19.02%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

Why is Vertex Pharmaceuticals's return on equity so high?

Net margin
32.7%
profit on each dollar of sales
Asset turnover
0.46×
sales on each dollar of assets
Equity multiplier
1.40×
assets on each dollar of equity
Return on equity
21.2%
FY2025
  • FY202532.7% × 0.46 × 1.40 = 21.2%
  • FY2024-4.9% × 0.49 × 1.37 = -3.3%
  • FY202336.7% × 0.43 × 1.29 = 20.6%
  • FY202237.2% × 0.49 × 1.30 = 23.9%
  • FY202130.9% × 0.56 × 1.33 = 23.2%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today19.02%3.98B20.91B
FY202531 Dec 202521.18%3.95B18.67B
FY202431 Dec 2024-3.26%-535.60M16.41B
FY202331 Dec 202320.59%3.62B17.58B
FY202231 Dec 202223.88%3.32B13.91B
FY202131 Dec 202123.19%2.34B10.10B
FY202031 Dec 202031.22%2.71B8.69B
FY201931 Dec 201919.34%1.18B6.09B
FY201831 Dec 201847.06%2.09B4.44B
FY201731 Dec 20174.52%91.64M2.03B
FY201631 Dec 2016-7.27%-84.03M1.16B
FY201531 Dec 2015-62.57%-588.18M939.97M
FY201431 Dec 2014-69.09%-742.75M1.08B
FY201331 Dec 2013-50.69%-687.55M1.36B
FY201231 Dec 2012-5.12%-51.14M999.18M
FY201131 Dec 20115.23%41.18M786.84M
FY201031 Dec 2010-149.74%-754.63M503.97M
FY200931 Dec 2009-58.57%-642.18M1.10B
FY200831 Dec 2008-192.51%-459.85M238.87M
FY200731 Dec 2007-144.23%-391.28M271.30M
FY200631 Dec 2006-40.89%-206.89M505.94M
FY200531 Dec 2005-85.05%-203.42M239.18M
FY200431 Dec 2004-469.08%-166.25M35.44M
FY200331 Dec 2003-102.03%-196.77M192.85M
FY200231 Dec 2002-28.69%-108.62M378.58M
FY200131 Dec 2001-13.93%-66.23M475.35M
FY200031 Dec 2000-7.72%-39.66M514.01M
FY199931 Dec 1999-19.60%-41.00M209.23M
FY199831 Dec 1998-13.44%-33.10M246.20M
FY199731 Dec 1997-7.17%-19.80M276.00M
FY199631 Dec 1996-30.58%-40.00M130.80M
FY199531 Dec 1995-25.21%-21.50M85.30M
FY199431 Dec 1994-16.68%-17.60M105.50M
FY199331 Dec 19934.04%2.00M49.50M
FY199231 Dec 1992-19.36%-8.50M43.90M
FY199131 Dec 1991-9.77%-5.10M52.20M
FY199031 Dec 1990-82.69%-4.30M5.20M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Debt to equity,Current ratio,All ratios

Common questions about Vertex Pharmaceuticals's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.